Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Title

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Authors

Keywords

Biomarkers, CDK4, CDK6, Cyclin-dependent kinase, LY2835219

Journal

Clinical Lung Cancer

Volume 17, Issue 1, Pages 80-84

Publisher

Elsevier BV

Online

2015-08-19

DOI

10.1016/j.cllc.2015.08.003